Loading articles...
CAR-T Therapy Versus Bispecific Antibodies
The next phase of CAR-T addresses its biggest limitations: off-the-shelf allogeneic products, in vivo gene delivery, and bispecific antibodies that redirect T cells without any gene engineering. Sarah Mitchell and James Carter explore where the technology i...
Small Molecules VS CAR-T In CLL
By the time CAR-T arrived in CLL, the disease had already been transformed by BTK inhibitors and venetoclax. TRANSCEND CLL 004 showed 18% CR in BTKi/venetoclax-refractory disease. Sarah Mitchell and James Carter explore why CLL is harder for CAR-T, where it...
Moving CAR-T To Earlier Myeloma Lines
Ciltacabtagene autoleucel achieved a 97% overall response rate and 67% complete response in triple-class refractory multiple myeloma - numbers not thought achievable a decade ago. CARTITUDE-4 has now moved it to the second line. Sarah Mitchell and James Car...
CAR-T Masterstroke Or Biological Chaos?
In 2012, a 6-year-old with relapsed ALL became the first child successfully treated with CAR-T cell therapy. That case launched a revolution. Sarah Mitchell and James Carter explain how chimeric antigen receptor T cells are engineered, why CD19 was the firs...
Why Cheaper Humira Alternatives Face Resistance
Adalimumab biosimilars cut NHS spend by over 50% while treating more patients. NOR-SWITCH and subsequent trials consistently show switching from reference biologic to biosimilar is safe. Sarah Mitchell and James Carter explain the regulatory science, the no...
Stopping Spinal Fusion Or Protecting The Gut?
PsA is not RA with skin, and axSpA is not RA in the spine. The biologic hierarchy shifts significantly across the spondyloarthropathy spectrum - IL-17 and IL-23 inhibitors dominate, anti-TNF has uveitis caveats, and IBD comorbidity changes everything. Sarah...
Chasing Absolute Zero In Rheumatoid Arthritis
Treat-to-target transformed RA outcomes - not through new drugs but through rigorous measurement and escalation discipline. Sarah Mitchell and James Carter cover the evidence base, the disease activity tools, the window of opportunity in early RA, and when ...
The ORAL Surveillance JAK Inhibitor Controversy
ORAL Surveillance showed tofacitinib carried higher cardiovascular and malignancy risk than anti-TNF in high-risk RA patients - triggering a class-wide boxed warning. But was the signal overgeneralised? Sarah Mitchell and James Carter unpack the data, the c...
Managing Acute Heart Failure And Cardiogenic Shock
Acute decompensated heart failure drives over one million hospital admissions annually. 30-day readmission rates are 25%. When the heart cannot compensate, the tools change entirely - IV diuretics, inotropes, mechanical circulatory support. Sarah Mitchell a...
Semaglutide For Obese Heart Failure Patients
More than 80% of HFpEF patients are overweight or obese. STEP-HFpEF showed semaglutide 2.4mg improved symptoms by 16 points on the KCCQ and reduced weight by 13.3% - now a Class IIa ESC recommendation. Sarah Mitchell and James Carter explore why treating th...